Schwab Charles Investment Management Inc. Sells 12,302 Shares of Intrexon Corp (XON)

Schwab Charles Investment Management Inc. reduced its holdings in Intrexon Corp (NYSE:XON) by 5.8% during the 3rd quarter, Holdings Channel reports. The fund owned 198,148 shares of the biotechnology company’s stock after selling 12,302 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Intrexon were worth $3,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in XON. Alliancebernstein L.P. lifted its stake in shares of Intrexon by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock valued at $786,000 after purchasing an additional 200 shares during the period. Legal & General Group Plc lifted its stake in shares of Intrexon by 2.1% in the 2nd quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock valued at $454,000 after purchasing an additional 393 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Intrexon by 26.3% in the 2nd quarter. Pacer Advisors Inc. now owns 9,282 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 1,930 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Intrexon by 4.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock valued at $1,425,000 after purchasing an additional 2,468 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Intrexon by 1.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock valued at $4,512,000 after purchasing an additional 3,234 shares during the period. 77.45% of the stock is currently owned by institutional investors and hedge funds.

Intrexon Corp (XON) opened at $14.71 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1,780.00, a price-to-earnings ratio of -13.13 and a beta of 1.33. Intrexon Corp has a 12-month low of $10.26 and a 12-month high of $26.99.

Several equities analysts recently issued reports on XON shares. JMP Securities reiterated an “outperform” rating and issued a $42.00 target price on shares of Intrexon in a research note on Thursday, October 5th. Griffin Securities reiterated a “buy” rating and issued a $55.00 target price on shares of Intrexon in a research note on Friday, October 6th. Northland Securities reiterated a “buy” rating and issued a $27.00 target price on shares of Intrexon in a research note on Friday, October 6th. Zacks Investment Research cut shares of Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Stifel Nicolaus boosted their target price on shares of Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $38.50.

ILLEGAL ACTIVITY NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thestockobserver.com/2018/01/14/schwab-charles-investment-management-inc-sells-12302-shares-of-intrexon-corp-xon.html.

Intrexon Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply